Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.

Osteosarcoma is the most frequent primary malignant tumor of bone with a high propensity for metastasis. We have previously showed that ezrin expression is necessary for metastatic behavior in a murine model of osteosarcoma (K7M2). In this study, we found that a mechanism of ezrin-related metastatic behavior is linked to an Akt-dependent mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (S6K1)/eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) pathway. Suppression of ezrin expression either by antisense transfection or by small interfering RNAs or disruption of ezrin function by transfection of a dominant-negative ezrin-T567A mutant led to decreased expression and decreased phosphorylation of both S6K1 and 4E-BP1. Proteosomal inhibition by MG132 reversed antisense-mediated decrease of S6K1 and 4E-BP1 protein expression, but failed to affect the effect of ezrin on phosphorylation of S6K1 and 4E-BP1. Blockade of the mTOR pathway with rapamycin or its analog, cell cycle inhibitor-779 led to significant inhibition of experimental lung metastasis in vivo. These results suggest that blocking the mTOR/S6K1/4E-BP1 pathway may be an appropriate target for strategies to reduce tumor cell metastasis.

[1]  Christine C. Hudson,et al.  A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.

[2]  M. Arpin,et al.  Membrane-actin microfilament connections: an increasing diversity of players related to band 4.1. , 1994, Current opinion in cell biology.

[3]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[4]  M. Hollingsworth,et al.  High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. , 1999, Biochemical and biophysical research communications.

[5]  F. Luan,et al.  Rapamycin is an effective inhibitor of human renal cancer metastasis. , 2003, Kidney international.

[6]  S. Schreiber,et al.  Erratum: Control of p70 S6 kinase by kinase activity of FRAP in vivo (Nature (1995) 377 (441-446)) , 1995 .

[7]  W. Jiang,et al.  Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. , 1999, Journal of cell science.

[8]  N. Takahashi,et al.  Ezrin/Radixin/Moesin (ERM) Proteins Bind to a Positively Charged Amino Acid Cluster in the Juxta-Membrane Cytoplasmic Domain of CD44, CD43, and ICAM-2 , 1998, The Journal of cell biology.

[9]  Javed Khan,et al.  Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators , 2004, Nature Medicine.

[10]  T. Rutherford,et al.  Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. , 1999, Cancer letters.

[11]  S. Schreiber,et al.  A Signaling Pathway to Translational Control , 1996, Cell.

[12]  Christian Roy,et al.  Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin , 2004, The Journal of cell biology.

[13]  R. Abraham,et al.  The Rapamycin-Binding Domain Governs Substrate Selectivity by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[14]  E. Van Obberghen,et al.  In Rat Hepatocytes Glucagon Increases Mammalian Target of Rapamycin Phosphorylation on Serine 2448 but Antagonizes the Phosphorylation of Its Downstream Targets Induced by Insulin and Amino Acids* , 2004, Journal of Biological Chemistry.

[15]  A. Bretscher,et al.  cDNA cloning and sequencing of the protein‐tyrosine kinase substrate, ezrin, reveals homology to band 4.1. , 1989, The EMBO journal.

[16]  A. Gautreau,et al.  Morphogenic Effects of Ezrin Require a Phosphorylation-Induced Transition from Oligomers to Monomers at the Plasma Membrane , 2000, The Journal of cell biology.

[17]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[18]  A. Gingras,et al.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. , 1999, Annual review of biochemistry.

[19]  C. Underhill,et al.  CD44: the hyaluronan receptor. , 1992, Journal of cell science.

[20]  J. Avruch,et al.  Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism* , 1998, The Journal of Biological Chemistry.

[21]  Stephen M Hewitt,et al.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.

[22]  A. Vaheri,et al.  Association of Ezrin with Intercellular Adhesion Molecule-1 and -2 (ICAM-1 and ICAM-2) , 1998, The Journal of Biological Chemistry.

[23]  S. Schreiber,et al.  Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.

[24]  J. Jääskeläinen,et al.  The ezrin protein family: membrane-cytoskeleton interactions and disease associations. , 1997, Current opinion in cell biology.

[25]  K. Sakaguchi,et al.  The ezrin-like family of tyrosine kinase substrates: receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation. , 1993, Oncogene.

[26]  L. Helman,et al.  Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. , 2002, Neoplasia.

[27]  K. Kaibuchi,et al.  Rho-Kinase Phosphorylates COOH-terminal Threonines of Ezrin/Radixin/Moesin (ERM) Proteins and Regulates Their Head-to-Tail Association , 1998, The Journal of cell biology.

[28]  A. Gautreau,et al.  Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Meltzer,et al.  Metastasis-associated differences in gene expression in a murine model of osteosarcoma. , 2001, Cancer research.

[30]  A. Bretscher,et al.  ERM proteins and merlin: integrators at the cell cortex , 2002, Nature Reviews Molecular Cell Biology.

[31]  D. Alessi,et al.  Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. , 1999, The Biochemical journal.

[32]  S. Tsukita,et al.  ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. , 1997, Current opinion in cell biology.

[33]  R. Pearson,et al.  Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k , 1997, The EMBO journal.

[34]  N. Sato,et al.  ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons , 1994, The Journal of cell biology.